Low-density lipoprotein receptor-related protein 1B (LRP1B)

Low-density lipoprotein receptor-related protein 1B (LRP1B) is a very large member of the LDL receptor family that acts as a cell surface endocytic receptor and is involved in receptor-mediated endocytosis and cell signaling[2][5]. LRP1B highly resembles LRP1 structurally but is encoded by a distinct gene. It regulates diverse physiological processes including cell proliferation, migration, invasion, and amyloid precursor protein trafficking, thus influencing both tumor cell behavior and neuronal integrity[2][4]. LRP1B is regarded as a tumor suppressor: it is frequently inactivated or mutated in several human cancers, and its loss is associated with altered tumor biology[2][3][4]. Genetic variants of LRP1B are also associated with obesity traits, and there is emerging evidence for its role in neurodegenerative and cardiovascular diseases[3][4]. LRP1B is not currently the direct target of any approved drug, but its mutational status is increasingly being used as a predictive biomarker for immune checkpoint inhibitor therapies, making it clinically relevant for translational research and patient stratification[2].

Other names

LRP-1BLRP-DITLRPDITLow-density lipoprotein receptor-related protein-deleted in tumorLRP-deleted in tumorslow density lipoprotein receptor related protein-deleted in tumorlow density lipoprotein receptor-related protein 1Blow density lipoprotein-related protein 1B (deleted in tumors)

Drugs do not primarily act by targeting LRP1B, but tumors with LRP1B mutations (loss-of-function) exhibit altered response to some immunotherapies (mechanism: modulation of tumor microenvironment and immune recognition)[2].